Voyager Therapeutics, Inc.VYGRNASDAQ
Loading
VYGR Revenue Growth (YoY Quarterly)•+144.28%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+144.28%
+190.0pp
+79.61%
+125.3pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+1.24%
-0.4pp
+1.24%
-0.4pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -93.03% | -66.83% | -82.42% | -45.73% | +144.28% |
| Gross Profit Growth | -92.92% | -64.67% | +0.00% | -45.73% | +79.61% |
| EBITDA Growth | -163.68% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -170.84% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -161.15% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -146.09% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -147.20% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +31.81% | +2.16% | +1.64% | +1.65% | +1.24% |
| Weighted Average Shares Diluted Growth | +28.61% | +2.16% | +1.64% | +1.65% | +1.24% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -164.48% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -168.08% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -94.68% | -38.96% | -22.33% | -79.47% | -60.79% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +11.89% | -24.78% | -26.16% | -32.33% | -35.81% |
| Book Value per Share Growth | -3.77% | -21.69% | -28.44% | -34.53% | -35.39% |
| Debt Growth | +115.46% | -12.39% | -14.35% | -15.39% | -16.53% |
| R&D Expense Growth | +45.71% | +21.74% | -9.06% | +18.60% | +1.04% |
| SG&A Expenses Growth | -12.19% | +12.00% | +3.39% | -0.92% | +3.58% |
1 / 4